Oxford Biomedica PLC Oxford BioMedica Board Change (9950X)
12 May 2016 - 4:00PM
UK Regulatory
TIDMOXB
RNS Number : 9950X
Oxford Biomedica PLC
12 May 2016
Oxford BioMedica Board Change
Oxford, UK - 12 May 2016: Oxford BioMedica plc ("Oxford
BioMedica" or "the Group") (LSE:OXB), a leading gene and cell
therapy group, today announces that Dr Paul Blake will leave the
Group when his current contract expires at the end of August 2016.
Dr Blake was appointed to Oxford BioMedica's Board as a
non-executive Director in January 2010 and subsequently he became
Chief Development Officer in September 2014.
John Dawson, Chief Executive Officer of Oxford BioMedica, said:
"Paul has made a significant contribution to Oxford BioMedica in
both his non-executive and executive capacities. I thank Paul for
his contribution to the development and continued success of Oxford
BioMedica and wish him the best for his future."
-Ends-
For further information,
please contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive 783 000
Officer
Tim Watts, Chief Financial
Officer
Financial and corporate communications Tel: +44 (0)20 3709
enquiries: 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew
Neal/Chris Welsh/Laura Thornton
Notes for editors
About Oxford BioMedica(R)
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
group focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ) through which the Group develops in vivo and ex
vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, GSK, and Immune
Design, through which it has long-term economic interests in other
potential gene and cell therapy products. Oxford BioMedica is based
across several locations in Oxfordshire, UK and employs more than
230 people. Further information is available at
www.oxfordbiomedica.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAEANSFFFEKEFF
(END) Dow Jones Newswires
May 12, 2016 02:00 ET (06:00 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024